ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1011

Trends in Fracture Rates Among Veterans with Ankylosing Spondylitis

Sali Merjanah1, Jean Liew1, John Bihn2, Nathanael Fillmore2, Nhan Do3 and Maureen Dubreuil4, 1Boston University, Boston, MA, 2VA Boston Healthcare System, Boston, MA, 3VA Boston Healthcare System, Boston University School of Medicine, Boston, MA, 4Department of Rheumatology, Boston University School of Medicine, Boston, MA

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), Epidemiology, Fracture

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: A meta-analysis demonstrated that the risk of vertebral fractures in Ankylosing Spondylitis (AS) is doubled compared to non-AS comparators. Increased fracture risk in AS is thought to be due to local bone remodeling and systemic inflammatory effects. However, data are limited regarding changes in fracture rates in AS over time. We assessed fracture rates in AS and general population comparators and performed an interrupted time series to assess whether fracture rates have changed since the introduction of biologics for AS treatment.

Methods: We used the national Veterans Affairs Corporate Data Warehouse and included adults ≥ 18 years old with ≥1 ICD-9/10 code for AS from an outpatient data source from 1999 to 2021, and at least one disease modifying antirheumatic drug medication fill or administration. Subjects were excluded if they had ≥1 ICD-9/-10 code of rheumatoid arthritis or psoriatic arthritis, had missing age data, or a history of the outcome of interest (radius, femoral or vertebral fracture) prior to inclusion. As comparators, we selected a 20% random sample of adults ≥18 years old without a prior AS diagnosis. For each AS subject, follow up time began at the time of AS diagnosis. Subjects were followed until they had a fracture, reached age 90, died, were disenrolled from the VA, or at the study’s end in May 2021.

Statistical analysis:Annual incidence rates were calculated as the number of incident fractures divided by the number of person-years (PY) separately for the AS and comparison groups. Rates were stratified by sex. For male patients, rates were also stratified for age and race. We directly standardized fracture rates to the structure of the cohort in 2017. To examine trends over time we calculated the adjusted relative risk of fracture in the AS group compared to the comparison group for each year. We then performed an interrupted time series analysis to compare rates of fractures from 2001-2003, and then from 2004-2021 as estimates of fracture rates in the pre-TNFi and TNFi eras. In this analysis we divided standardized fracture rates in AS by the comparator rates to account for a secular trend in fractures.

Results: As of 2017, the baseline year used for standardization, we identified 3,983 patients with AS (median age 52.61 years, 92.4% men, 77.2% white) and 1,152,573 randomly selected general population comparators (median age 64.13 years, 89.5% men, 69.8% white; Table 1).

The annual incidence rate of fractures increased among those with AS, from 2.1 per 1000 PY in 1999 to 22.8 in 2021. The rate also increased among comparators from 0.4 to 8.3. The rate ratio (AS/comparators) appear stable over the past 2 decades (Figure 1).

The interrupted time series showed rate of fractures in the TNFi era that was 15 per 1000 PY greater than the rate in the pre-TNFi era (4 per 1000 PY; Figure 2) for people with AS.

Conclusion: Our study showed increasing fracture incidence rates for both the AS comparator groups. This rate of fractures was increased in the TNFi era (2004-2021) relative to the pre-TNFi era. Understanding the fracture risk in AS patients and identifying the risk factors for developing fractures are important to investigate treatment interventions.

Supporting image 1

Table 1. Demographics and clinical characteristics of AS and comparator cohorts

Supporting image 2

Figure 1. Fracture rates for AS, comparators and the Ratio (AS/Comparator)

Supporting image 3

Figure 2. Fracture rate per 1000 PY among those with AS. Each dot represents the fracture rate in a 6-month period. The trend in fracture rates fit from observed data is shown as a solid line. The pre-TNFi period (2000_2003) slope is extended as a dashed line to allow comparison of the baseline period slope with the observed data slope in the TNFi period (2004_2021). Compared to the pre-TNFi era, the rate of fractures in the TNFi era is increased by 15 per 1000 PY.


Disclosures: S. Merjanah, None; J. Liew, None; J. Bihn, None; N. Fillmore, None; N. Do, None; M. Dubreuil, Amgen, UCB Pharma, Pfizer.

To cite this abstract in AMA style:

Merjanah S, Liew J, Bihn J, Fillmore N, Do N, Dubreuil M. Trends in Fracture Rates Among Veterans with Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/trends-in-fracture-rates-among-veterans-with-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trends-in-fracture-rates-among-veterans-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology